Literature DB >> 8166714

Different NH2-terminal form with 12 additional residues of alpha 2-plasmin inhibitor from human plasma and culture media of Hep G2 cells.

T Koyama1, Y Koike, S Toyota, F Miyagi, N Suzuki, N Aoki.   

Abstract

alpha 2-Plasmin inhibitor (alpha 2PI) was purified from plasma or from the culture media of Hep G2 cells by one-step immunoaffinity chromatography procedure. Majority of alpha 2PI purified from plasma was the previously recognized plasma alpha 2PI with NH2-terminal Asn (Asn-alpha 2PI), whereas majority of alpha 2PI purified from the culture media was retaining the "pro" peptide of 12 amino acids with NH2-terminal Met (Met-alpha 2PI). When Hep G2 cells were cultured in serum-free media, the alpha 2PI secreted to the media was totally in a form of Met-alpha 2PI. Incubation of Met-alpha 2PI with human plasma induced the complete conversion of Met-alpha 2PI to Asn-alpha 2PI. The results indicate that alpha 2PI is synthesized and secreted from liver cells as Met-alpha 2PI and Met-alpha 2PI is converted to Asn-alpha 2PI by proteolytic cleavage in plasma during the circulation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8166714     DOI: 10.1006/bbrc.1994.1465

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Noncovalent interaction of alpha(2)-antiplasmin with fibrin(ogen): localization of alpha(2)-antiplasmin-binding sites.

Authors:  Galina Tsurupa; Sergiy Yakovlev; Patrick McKee; Leonid Medved
Journal:  Biochemistry       Date:  2010-09-07       Impact factor: 3.162

2.  The human alpha(2)-plasmin inhibitor: functional characterization of the unique plasmin(ogen)-binding region.

Authors:  Simon S Gerber; Sofia Lejon; Michael Locher; Johann Schaller
Journal:  Cell Mol Life Sci       Date:  2010-01-29       Impact factor: 9.261

Review 3.  The plasmin-antiplasmin system: structural and functional aspects.

Authors:  Johann Schaller; Simon S Gerber
Journal:  Cell Mol Life Sci       Date:  2010-12-07       Impact factor: 9.261

4.  Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor α2-antiplasmin.

Authors:  K N Lee; K W Jackson; V J Christiansen; E K Dolence; P A McKee
Journal:  J Thromb Haemost       Date:  2011-05       Impact factor: 5.824

5.  The effect of a single nucleotide polymorphism on human alpha 2-antiplasmin activity.

Authors:  Victoria J Christiansen; Kenneth W Jackson; Kyung N Lee; Patrick A McKee
Journal:  Blood       Date:  2007-02-22       Impact factor: 22.113

6.  Evidence that alpha2-antiplasmin becomes covalently ligated to plasma fibrinogen in the circulation: a new role for plasma factor XIII in fibrinolysis regulation.

Authors:  M W Mosesson; K R Siebenlist; I Hernandez; K N Lee; V J Christiansen; P A McKee
Journal:  J Thromb Haemost       Date:  2008-06-16       Impact factor: 5.824

Review 7.  Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk.

Authors:  Katherine Kearney; Darren Tomlinson; Kerrie Smith; Ramzi Ajjan
Journal:  Cardiovasc Diabetol       Date:  2017-03-09       Impact factor: 9.951

8.  Criteria for the Specific Measurement of Plasmin Inhibitor Activity Using an Enzymatic Procedure.

Authors:  Piet Meijer; Michel Hanss; Ulla Christensen; Bjorn Wiman; Kees Kluft
Journal:  EJIFCC       Date:  2001-07-22

9.  Systemic Effects of Hemorrhagic Snake Venom Metalloproteinases: Untargeted Peptidomics to Explore the Pathodegradome of Plasma Proteins.

Authors:  Luciana Bertholim; Alison F A Chaves; Ana K Oliveira; Milene C Menezes; Amanda F Asega; Alexandre K Tashima; Andre Zelanis; Solange M T Serrano
Journal:  Toxins (Basel)       Date:  2021-10-28       Impact factor: 4.546

10.  Plasma Proteolytic Cascade Activation during Neonatal Cardiopulmonary Bypass Surgery.

Authors:  Susan A Maroney; Julie A Peterson; Wes Zwifelhofer; Nicholas D Martinez; Ke Yan; Rachel S Bercovitz; Ronald K Woods; Alan E Mast
Journal:  Thromb Haemost       Date:  2018-08-07       Impact factor: 5.249

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.